Form 8-K - Current report:
SEC Accession No. 0001564590-21-013612
Filing Date
2021-03-16
Accepted
2021-03-16 16:39:55
Documents
14
Period of Report
2021-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aveo-8k_20210316.htm   iXBRL 8-K 41722
2 EX-99.1 aveo-ex991_6.htm EX-99.1 324117
3 GRAPHIC gdqvokdsxuo1000001.jpg GRAPHIC 14172
  Complete submission text file 0001564590-21-013612.txt   535288

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aveo-20210316.xsd EX-101.SCH 5792
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aveo-20210316_lab.xml EX-101.LAB 18717
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aveo-20210316_pre.xml EX-101.PRE 11185
7 EXTRACTED XBRL INSTANCE DOCUMENT aveo-8k_20210316_htm.xml XML 3409
Mailing Address 30 WINTER STREET BOSTON MA 02108
Business Address 30 WINTER STREET BOSTON MA 02108 857-400-0101
AVEO PHARMACEUTICALS, INC. (Filer) CIK: 0001325879 (see all company filings)

EIN.: 043581650 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34655 | Film No.: 21746394
SIC: 2834 Pharmaceutical Preparations